Huahui Health Secures $20M HH160 Deal

• Huahui Health announced a global exclusive option, license and collaboration with BeOne Medicines for the trispecific oncology antibody HH160.
• BeOne will pay USD 20 million upfront, USD 100 million option‑exercise fee, and up to USD 1.9 billion in milestones plus royalties.
• Huahui’s first product Libevitug injection received conditional NMPA approval in Jan 2026 for chronic hepatitis D and holds Breakthrough Designations from NMPA and FDA.
• HH160 targets PD‑1, CTLA‑4 and VEGF‑A, aiming to boost efficacy, tumor‑specific distribution and reduce adverse effects.